Alessia Brix
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Alessia Brix has a total of 3 co-authors. Here are the top co-authors by number of shared publications:
- Anna Pistocchi
Department of Medical Biotechnology and Translational Medicine, Università Degli Studi di Milano, L.I.T.A, Milan, Italy
1 shared publication - Marco Cafora
Department of Medical Biotechnology and Translational Medicine, University of Milan, Milan, Italy
1 shared publication - Massimo Aureli
Department of Medical Biotechnology and Translational Medicine, University of Milano, Segrate, Milano, Italy
1 shared publication
Latest Publications
- Open Access
- 25 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3715
Animal Models to Translate Phage Therapy to Human Medicine
Phagotherapy, the use of bacteriophages to fight bacterial infections as an alternative to antibiotic treatments, has become of increasing interest in the last years. This is mainly due to the diffusion of multi-drug resistant (MDR) bacterial infections that constitute a serious issue for public health. Phage therapy is gaining favor due to its success in agriculture and veterinary treatments and its extensive utilization for human therapeutic protocols in the Eastern world. In the last decades, some clinical trials and compassionate treatments have also been performed in the Western world, indicating that phage therapy is getting closer to its introduction in standard therapy protocols. However, several questions concerning the use of phages in human therapeutic treatments are still present and need to be addressed. In this review, we illustrate the state of art of phage therapy and examine the role of animal models to translate these treatments to humans.
- 25 May 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (10) , 3715
Open AccessAnimal Models to Translate Phage Therapy to Human Medicine
Phagotherapy, the use of bacteriophages to fight bacterial infections as an alternative to antibiotic treatments, has become of increasing interest in the last years. This is mainly due to the diffusion of multi-drug resistant (MDR) bacterial infections that constitute a serious issue for public health. Phage therapy is gaining favor due to its success in agriculture and veterinary treatments and its extensive utilization for human therapeutic protocols in the Eastern world. In the last decades, some clinical trials and compassionate treatments have also been performed in the Western world, indicating that phage therapy is getting closer to its introduction in standard therapy protocols. However, several questions concerning the use of phages in human therapeutic treatments are still present and need to be addressed. In this review, we illustrate the state of art of phage therapy and examine the role of animal models to translate these treatments to humans.